🕒 Last update: loading…

Stock Lipocine Inc. LPCN

Lipocine Inc. — Investlytic score 2/5 on the five criteria.

-
-
40/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 2/5 criteria met.

  • ❌ Price trend failed
  • ⚠️ Mixed growth
  • ✅ Debt passed
  • ❌ P/E failed
  • ✅ Correction passed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: -70.36%

Price change 2019 → 2020: 252.98%

Price change 2020 → 2021: -27.12%

Price change 2021 → 2022: -59.82%

Price change 2022 → 2023: -58.79%

Price change 2023 → 2024: 74.91%

Price change 2024 → 2025: 64.55%

Price change 2025 → 2026: -74.22%

Price change 2026 (year to date): -74.12%

Financial growth

Revenue CAGR (8 years): 24.43%

Earnings CAGR (8 years): N/A

Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.

Debt

Debt-to-equity ratio: 0.03

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -1.15

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 19.14% from the high over 6 months.

Correction between 10.0% and 20.0% (target range).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Lipocine Inc.–0.03–🔒
Geratherm Medical AG–0.13−1.2 %–
Femasys Inc.–0.80+16.2 %–
Exlites Holdings International, Inc.–0.00+82.7 %–
Aelis Farma S.A.–1.49+49.1 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Lipocine Inc. over the latest fiscal years.

Revenue
2.0 m USD
fiscal year 2025
Net income
-9.6 m USD
fiscal year 2025
Net margin
-487.1 %
fiscal year 2025
Average annual growth
+64.3 %
Revenue growth over 5 years
Market cap
14.1 m USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
2019164,990-13.0 m-7,883.7 %n/a
202116.1 m-634,399-3.9 %+9,682.9 %
2022500,000-10.8 m-2,151.7 %-96.9 %
2023-2.9 m-16.4 m573.6 %-670.2 %
202411.2 m8,3520.1 %n/a
20252.0 m-9.6 m-487.1 %-82.3 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Lipocine Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
-9.19
risk zone (below 1.81)
Piotroski Score
1 / 9
0 to 3: fragile accounts
DCF Value
0.670 USD
DCF below share price · share price 1.57 USD, gap -57.3 %
Net Debt / EBITDA
0.28 x
low debt
Fiscal year20212022202320242025
Cash and investments44.6 m32.5 m22.0 m21.6 m14.9 m
Total Debt2.3 m000449,591
Net Debt-639,727-3.1 m-4.8 m-6.2 m-4.8 m
Equity45.6 m35.6 m20.4 m21.0 m14.5 m
Total assets52.5 m37.5 m23.0 m22.5 m17.0 m
Operating cash flow-4.4 m-12.0 m-11.9 m-1.2 m-9.8 m
Investments (capex)7,591133,83113,16790,0860
Free cash-flow-4.4 m-12.1 m-11.9 m-1.3 m-9.8 m
Share buybacks021,700000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-1.19 x
Price / book value0.63 x
Return on Equity (ROE)-46.5 %
Return on Invested Capital (ROIC)-47.6 %
Net margin-249.2 %
Debt / equity0.00 x
Current ratio11.36 x
Free cash-flow yield-75.0 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 16/11/2026.

+

Valuation and competitors

Lipocine Inc. compared with its sector on the same exchange and with its main competitors.

Sector median P/E
20.8
healthcare, Nasdaq
Sector over 10 years
28.2
10-year median, range 20.4 to 45.8

Direct competitors

CompanyMarket cap (USD)P/ENet margin
Lipocine Inc.12.9 mn/a-487.1 %
Adlai Nortye Ltd. ANL546 mn/a-710.6 %
BioLineRx Ltd. BLRX8.5 mn/a-99.6 %
GeoVax Labs, Inc. GOVX1.6 mn/a-862.3 %
Edesa Biotech, Inc. EDSA20.6 mn/a0.0 %
ProMIS Neurosciences, Inc. PMN37.3 mn/a0.0 %
Ernexa Therapeutics Inc. ERNA3.1 mn/a0.0 %
Lunai Bioworks Inc. LNAI829,677n/a-6,852.0 %
Moleculin Biotech, Inc. MBRX8.9 mn/a0.0 %
Sector median (Nasdaq)20.8

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering Lipocine Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
9 analysts

Breakdown of ratings

strong buy 0buy 7hold 2sell 0strong sell 0

Price targets: published for companies listed in the United States only.

Track record against expectations: reported EPS above consensus 8 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Lipocine Inc.

Free float
95.0 %
share of freely traded shares
Large funds tracked
10
hold the stock as of 2026Q2
Executives (insiders)
5 / 0
5 purchases, 0 sales in 130 days

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
Vanguard Group221,8671.8 m0.0 %0.0 %2025Q4
Citadel Advisors162,442415,8520.0 %+458.5 %2026Q2
BlackRock89,272228,5360.0 %0.0 %2026Q2
Two Sigma Investments84,887217,3110.0 %+151.5 %2026Q2
Geode Capital Management74,477190,7610.0 %+18.0 %2026Q2
Renaissance Technologies69,209177,1750.0 %+79.8 %2026Q2
State Street44,814114,7240.0 %+100.0 %2026Q2
Northern Trust15,94240,8120.0 %+22.2 %2026Q2

Latest insider transactions

DatePersonSideAmount
13/11/2026Patel Mahesh V.purchase39,998 USD
12/11/2026Patel Mahesh V.purchase39,490 USD
30/09/2026Higuchi John W.purchase35,613 USD
29/09/2026Higuchi John W.purchase19,430 USD
28/09/2026Higuchi John W.purchase27,132 USD

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 16/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 22/10/2013
ISIN code
US53630X2036
Workforce
16
full-time employees
Chief executive
Mahesh V. Patel

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Lipocine Inc.

What is the Lipocine Inc. share price?

Latest recorded price: 1.71 USD on 13/11/2026, for a market cap of 14.1 m USD.

What is the revenue of Lipocine Inc.?

2.0 m USD for fiscal year 2025, with net income of -9.6 m USD (net margin -487.1 %).

What do analysts say about Lipocine Inc.?

Out of 9 analysts: 7 buy or strong buy, 2 hold, 0 sell or strong sell.

Is Lipocine Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US53630X2036).

How many employees does Lipocine Inc. have?

16 full-time employees according to the latest published profile.

Who runs Lipocine Inc.?

Mahesh V. Patel is the company's chief executive.

Which large funds own Lipocine Inc.?

As of 2026Q2, among the large funds tracked: Vanguard Group, Citadel Advisors, BlackRock, Two Sigma Investments, Geode Capital Management.

07

Similar stocks